Speciality: Oncology
Description:
Welcome to this insightful case presentation by Dr. Viraj Nevrekar. In it, he discusses the use of Dacomitinib in clinical practice, focusing on baseline treatment strategies and the current status of this targeted therapy. Dr. Nevrekar, a respected Key Opinion Leader (KOL) in oncology, provides a detailed overview of patient selection, efficacy data, and real-world outcomes associated with Dacomitinib. His expertise sheds light on how this EGFR inhibitor fits into modern treatment paradigms, particularly for non-small cell lung cancer (NSCLC) patients with specific mutations.
In this presentation, Dr. Nevrekar elaborates on the key considerations for initiating Dacomitinib, including patient profiling, dosing protocols, and managing adverse events. He also compares its performance with other EGFR TKIs, highlighting its unique benefits and challenges. By sharing real-world case studies, he offers valuable insights into optimizing treatment outcomes while minimizing toxicity, making this video essential for oncologists and healthcare professionals involved in lung cancer management.
Don’t miss this opportunity to learn from Dr. Nevrekar’s extensive experience with Dacomitinib. Stay tuned for more expert discussions and updates on cutting-edge therapies in oncology. Be sure to watch the full video and subscribe to future presentations that bridge the gap between research and clinical practice.
See More Webinars @ Hidoc Webinars
1.
Doctors say lung cancer is still the deadliest cancer, but hope is growing
2.
Child Death Rates Are Rising in the U. s. ; Water Beads Warning; Cancer Studies Retracted.
3.
FDA Leaders Explain Their Choice Regarding Cancer Risk Warning in CAR-T Investigation.
4.
The FDA has approved momelotinib for use in myelofibrosis patients who also have anemia.
5.
Virtual Reality Travel Reduces Cancer Pain.
1.
Clinical Decision-Making in Oligometastatic Cancer: A Case-Based Perspective
2.
Iron Homeostasis Throughout the Female Lifespan
3.
The Benefits and Side Effects of Vidaza Syndrome
4.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
5.
Exercise Rehabilitation in Hematologic Disease Survivorship
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
2.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V
3.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
4.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
5.
Preventing Blood Clots: The Importance of Venous Thromboembolism Management
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation